SCHEMBL15825152

SCHEMBL15825152

Brc1cc(-c2c[nH]nn2)ccn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.51
IMPDH2 P12268 1/20 0.32
CYP1A1 P04798 2/20 0.31
CYP1B1 Q16678 2/20 0.31
CCNB2 O95067 2/20 0.31
CDK1 P06493 2/20 0.31
CCNB1 P14635 2/20 0.31
PRKACA P17612 2/20 0.31
PRKACG P22612 2/20 0.31
PRKACB P22694 2/20 0.31
CSNK1A1 P48729 2/20 0.31
CSNK1D P48730 2/20 0.31
CSNK1E P49674 2/20 0.31
CLK1 P49759 2/20 0.31
GSK3B P49841 2/20 0.31
CSNK1G2 P78368 2/20 0.31
CDK5 Q00535 2/20 0.31
CDK5R1 Q15078 2/20 0.31
CCNB3 Q8WWL7 2/20 0.31
CSNK1G1 Q9HCP0 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29479605 0.81 NPC1 (0.40) IDO1
SCHEMBL28714631 0.81 NPC1 (0.40) IDO1
SCHEMBL30574759 0.79 IDO1 (0.51) IDO1DYRK1A
SCHEMBL6164730 0.74 METAP2 (0.49)
SCHEMBL19358820 0.73 KDM5A (0.36)
SCHEMBL22912663 0.73 IDO1 (0.55) IDO1CYP1A1CYP1B1DYRK1A
SCHEMBL6160014 0.73 IDO1 (0.50) IDO1CYP1A2
SCHEMBL3508077 0.72 METAP2 (0.45)
SCHEMBL5612895 0.72 LMNA (0.43) IDO1IMPDH2GSK3BPDPK1CYP1A2
SCHEMBL1646236 0.72 GP6 (0.37) IDO1CYP1A1CYP1B1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2934525-B1 THIAZOLE-SUBSTITUTED AMINOPYRIDINES AS SPLEEN TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME (US) 2019-05-08 EP disclosed
US-9598405-B2 Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2017-03-21 US disclosed
US-20150353535-A1 THIAZOLE-SUBSTITUTED AMINOPYRIDINES AS SPLEEN TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-12-10 US disclosed
EP-2934525-A1 THIAZOLE-SUBSTITUTED AMINOPYRIDINES AS SPLEEN TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-10-28 EP disclosed
WO-2014100314-A1 THIAZOLE-SUBSTITUTED AMINOPYRIDINES AS SPLEEN TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353535-A1 THIAZOLE-SUBSTITUTED AMINOPYRIDINES AS SPLEEN TYROSINE KINASE INHIBITORS SYK, BTK, JAK2 IDO1 515/4885IMPDH2 3311/4885CYP1A1 1950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.